Results from innovaTV 301 intended to serve as pivotal confirmatory trial for U.S. accelerated approval and to support global regulatory applications “Patients with cervical cancer have few treatment ...

COPENHAGEN, Denmark, and BOTHELL, Wash.; September 4, 2023 – Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) announced today that the Phase 3 innovaTV 301 global trial in recurrent or ...

Genmab A/S (Nasdaq: GMAB) and Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from the innovaTV 204 pivotal phase 2, single-arm clinical trial evaluating tisotumab vedotin as monotherapy in ...

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial evaluating the activity, safety and ...

Data from the study selected as a late-breaking abstract at ESMO, oral presentation is at 17:04 CEST on Sep 21, 2020 Genmab A/S (Nasdaq: GMAB) announced today that results from the phase 2 innovaTV ...

TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell ...

Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysis Trial results to be submitted for presentation at a ...

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm ...

TIVDAK demonstrated superior overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023 congress Results from ...

TIVDAK demonstrated statistically significant overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023 congress ...